市場調査レポート

商品コード

1762534

自動細胞処理システム市場業界動向と世界の予測 - 細胞治療処理ステップ別、事業規模別、エンドユーザー別、主要地域別

Automated Cell Processing System Market: Industry Trends and Global Forecasts - Distribution by Cell Therapy Processing Step, Scale of Operation, End User and Key Geographical Regions

出版日: 2025年07月04日
発行: Roots Analysis
ページ情報: 英文 184 Pages
納期: 即日から翌営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,799 705,884円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (One-Location Site License)

USD 6,999 1,029,482円

レポートPDFを同一所在地における特定事業ユニットに属する全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Department License)

USD 10,599 1,559,006円

レポートPDFを部署単位で12名様までご利用いただけるライセンスです。同一部署内であれば、地理的に同じ地点に存在する必要はありません。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 17,999 2,647,472円

レポートPDFを同社の国内外拠点における全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=147.09円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

自動細胞処理システム市場：概要

世界の自動細胞処理システムの市場規模は、今年2億2,000万米ドルとなりました。同市場は、予測期間中に16％のCAGRで拡大すると予測されています。

市場規模と機会分析は、以下のパラメータでセグメント化されています：

細胞治療処理ステップ

アフェレシス
分離
拡大
収穫
充填/仕上げ
凍結保存
解凍

事業規模

前臨床/臨床業務
商業組織

エンドユーザー

病院/ 医療センター/ クリニック/ 研究機関/ 学術機関
細胞治療メーカー/ 開発者

主要地域

北米
欧州
アジア太平洋
ラテンアメリカ
中東・北アフリカ

自動細胞処理システム市場：成長と動向

近年、バイオテクノロジー業界における数々の画期的な開発により、細胞療法候補の数が増加しています。事実、現在2,000以上の細胞・遺伝子治療候補が、無数の疾患適応症の治療のために研究されています。さらに、FDAが承認した治療法の結果は、腫瘍性疾患、希少疾患、慢性疾患の治療における細胞治療の大きな可能性を示しました。そのため、この治療法はここ数年、ヘルスケア業界の関係者から大きな注目を集めています。しかし、従来の細胞治療の製造工程は労働集約的で時間がかかるため、製造コストが高くなっていました。さらに、この手作業による細胞治療の製造工程は、バッチ間のばらつきにつながります。その結果、より洗練された、時間効率の高い製造ソリューションが新たに必要とされています。

Automated Cell Processing System Market-IMG1

長年にわたり、先進的で革新的な自動化ツールや技術がいくつか開発されてきました。これらの自動化されたクローズドな細胞処理システムは、先進的な細胞治療の製造に関連するコストを大幅に削減する可能性があることが実証されています。そのような自動化システムの一つ、すなわちGMP-In-A Boxは、スループットの向上、バッチ運転間のアイドル時間の短縮、手作業の削減など、いくつかの利点を提供します。このような自動化の利点により、細胞処理システム市場は今後有利な成長を遂げると思われます。

自動細胞処理システム市場：主要インサイト

本レポートでは、自動細胞処理システム市場の現状を掘り下げ、業界内の潜在的な成長機会を特定しています。本レポートの主な調査結果は以下の通りです。

現在、細胞治療の開発、生産、凍結保存の様々な段階を自動化するために、60を超える革新的な自動化・閉鎖システムが各社別開発されています。
市場情勢は断片化されており、既存の参入企業と新規参入者の両方が、異なる操作規模にわたって細胞を処理するための明確な特徴を持つ新規技術の開発に従事しています。
2010年以降、自動化されたクローズド細胞処理システムの開発に注力する新興企業が数多く設立され、この新分野は大手・中小企業両方の関心を集めています。
利用可能なシステムの大半は、現行の規制要件に準拠しています。例としては、BATON、NANT 001、ロボット細胞培養システム、ボルタループなどがあります。
この分野における利害関係者の関心の高まりは、最近の提携活動にも反映されています。最近の提携のほとんどは、新規技術に焦点を当てたもので、国際的な参入企業と国内企業の両方が積極的に参加しています。

Automated Cell Processing System Market-IMG2

この領域におけるパートナーシップの数はCAGR 24％で増加しており、これらのパートナーシップの70％以上が2018年以降に締結されています。
SA25無菌充填作業セル（vanrx pharma systems）の活用または統合に焦点を当てたいくつかの取引が、細胞治療製品の充填／仕上げのために締結されました。
競争優位性を追求するため、装置開発者は現在、それぞれの製品や提携製品への高度な機能の統合に注力しています。
大手製薬会社を含む、細胞治療の開発に携わる300以上の利害関係者を評価した結果、この分野の装置プロバイダーにとって、戦略的パートナーシップの可能性がいくつかあることが明らかになっています。
様々な処理工程におけるコスト削減の可能性を考慮すると、自動化・閉鎖型細胞治療システム市場は今後10年間、年率16％で成長すると予想されます。

Automated Cell Processing System Market-IMG3

自動細胞処理システム市場の参入企業例

AstraZeneca
Baxter
Bayer
Cytiva（Acquired by Danaher Corporation）
Cellular Therapeutics
Lonza
Merck
Pall（Acquired by Danaher Corporation）
Terumo BCT
ThermoGenesis

章の概要
大手製薬会社別取り組み
- AbbVieの取り組み
- Bristol Myers Squibbの取り組み
- Gilead Sciencesが取り組む取り組み
- GlaxoSmithKlineの取り組み
- Johnson & Johnsonの取り組み
- Novartisの取り組み
- Rocheの取り組み
- Sanofiの取り組み
- 武田薬品工業の取り組み
- 大手製薬会社の取り組みのサマリー

第9章パートナー候補

章の概要
範囲と調査手法
自動化・閉鎖型細胞治療処理システム：細胞治療開発の潜在的な戦略的パートナー
自動化・閉鎖型細胞治療処理システム：細胞治療製造の潜在的な戦略的パートナー

第10章ケーススタディ：部分自動化システムと完全自動化システムを使用した費用便益分析

第11章市場規模の評価と機会分析

章の概要
主要な前提と調査手法
自動化および閉鎖型細胞治療処理システム市場全体（2035年まで）

第12章結論

第13章インタビュー/アンケート記録

第14章付録1：表形式データ

第15章付録2：企業・団体一覧

図表

List of Tables

Table 3.1. Cell and Advanced Therapies: Key Applications
Table 3.2. Assessment of Key Cell Therapy Manufacturing Steps
Table 4.1. List of Automated and Closed Cell Therapy Processing Systems: Information on Cell Processing Step
Table 4.2. List of Automated and Closed Cell Therapy Processing Systems: Information on Types of Cells
Table 4.3. List of Automated and Closed Cell Therapy Processing Systems: Information on Type of Culture
Table 4.4. List of Automated and Closed Cell Therapy Processing Systems: Information on Scale of Operation
Table 4.5. List of Automated and Closed Cell Therapy Processing Systems: Information on Key Features
Table 4.6. List of Automated and Closed Cell Therapy Processing Systems: Information on Application Area
Table 4.7. List of Automated and Closed Cell Therapy Processing Systems: Information on Regulatory Certifications / Accreditations Obtained
Table 4.8. List of Automated and Closed Cell Therapy Processing Systems: Information on End Users
Table 4.9. List of Automated and Closed Cell Therapy Processing System Providers
Table 4.10. List of Automated and Closed Cell Therapy Processing System Providers: Information on Type of Support Service(s) Offered
Table 6.1. Cytiva: Key Highlights
Table 6.2. Cytiva: Product Portfolio
Table 6.3. Pall: Key Highlights
Table 6.4. Pall: Product Portfolio
Table 6.5. Terumo BCT: Key Highlights
Table 6.6. Terumo BCT: Product Portfolio
Table 6.7. Terumo BCT: Recent Developments and Future Outlook
Table 6.8. ThermoGenesis: Key Highlights
Table 6.9. ThermoGenesis: Product Portfolio
Table 6.10. ThermoGenesis: Recent Developments and Future Outlook
Table 7.1. Automated and Closed Cell Processing Systems: List of Partnerships, Since 2016
Table 8.1. Automated and Closed Cell Processing Systems: List of Big Pharma Players
Table 9.1. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Dendritic Cell Therapy Developers
Table 9.2. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Stem Cell Therapy Developers
Table 9.3. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: T-cell Therapy Developers
Table 9.4. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Natural Killer Cell Therapy Developers
Table 9.5. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Dendritic Cell Therapy Manufacturers
Table 9.6. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Stem Cell Therapy Manufacturers
Table 9.7. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: T-cell Therapy Manufacturers
Table 9.8. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Natural Killer Cell Therapy Manufacturers
Table 10.1. Comparative Analysis of Manual, Partially Automated and Fully Automated Cell Processing Systems, Since 2020
Table 10.2. Cost Saving Potential of Fully Automated Systems
Table 14.1. Automated and Closed Cell Therapy Processing Systems: Distribution by Cell Processing Step
Table 14.2. Automated and Closed Cell Therapy Processing Systems: Distribution by Types of Cells
Table 14.3. Automated and Closed Cell Therapy Processing Systems: Distribution by Type of Culture
Table 14.4. Automated and Closed Cell Therapy Processing Systems: Distribution by Scale of Operation
Table 14.5. Automated and Closed Cell Therapy Processing Systems: Distribution by Key Features
Table 14.6. Automated and Closed Cell Therapy Processing Systems: Distribution by Application Area
Table 14.7. Automated and Closed Cell Therapy Processing Systems: Distribution by Regulatory Certifications / Accreditations
Table 14.8. Automated and Closed Cell Therapy Processing Systems: Distribution by End Users
Table 14.9. Automated and Closed Cell Therapy Processing System Providers: Distribution Year of Establishment
Table 14.10. Automated and Closed Cell Therapy Processing System Providers: Distribution by Company Size
Table 14.11. Automated and Closed Cell Therapy Processing System Providers: Distribution by Type of Support Services Offered
Table 14.12. Automated and Closed Cell Therapy Processing System Providers: Distribution by Geographical Location
Table 14.13. Automated and Closed Cell Therapy Processing System Providers: Distribution by Geographical Location (Country-Wise)
Table 14.14. Leading Developers: Distribution by Number of Automated and Closed Cell Therapy Processing Systems
Table 14.15. Terumo BCT: Annual Revenues, Since FY 2016
Table 14.16. ThermoGenesis: Annual Revenues, Since FY 2016
Table 14.17. Recent Partnerships: Cumulative Distribution by Year of Partnership
Table 14.18. Recent Partnerships: Distribution by Type of Partnership Model Adopted
Table 14.19. Recent Partnerships: Year-wise Trend by Type of Partnership Model Adopted
Table 14.20. Recent Partnerships: Distribution by Type of Therapy
Table 14.21. Recent Partnerships: Distribution by Type of Therapy and Type of Partnership Model Adopted
Table 14.22. Recent Partnerships: Distribution by Cell Processing Step
Table 14.23. Recent Partnerships: Distribution by Automated and Closed Cell Processing System
Table 14.24. Recent Partnerships: Distribution by Type of Partner
Table 14.25. Recent Partnerships: Distribution by Type of Cell Processing Step and Developer
Table 14.26. Recent Partnerships: Most Active Players
Table 14.27. Recent Partnerships: Country-Wise Distribution
Table 14.28. Recent Partnerships: Intercontinental and Intracontinental Distribution
Table 14.29. Big Pharma Initiatives Summary
Table 14.30. Cost Saving Analysis: Comparative Analysis of Manual, Partially Automated and Fully Automated Processing Systems, Till 2035
Table 14.31. Cost Saving Potential of Fully Automated Processing Systems Based on Number of Patients
Table 14.32. Cost Saving Potential of Fully Automated Processing Systems Across Different Regions
Table 14.33. Overall Automated and Closed Cell Therapy Processing Systems Market, Till 2035 (USD Million)
Table 14.34. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Cell Therapy Processing Step (USD Million)
Table 14.35. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Apheresis Systems, Till 2035 (USD Million)
Table 14.36. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Separation Systems, Till 2035 (USD Million)
Table 14.37. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Expansion Systems, Till 2035 (USD Million)
Table 14.38. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Harvesting Systems, Till 2035 (USD Million)
Table 14.39. Automated and Closed Cell Therapy Processing Systems Market: Share of Fill Finish Systems, Till 2035 (USD Million)
Table 14.40. Automated and Closed Cell Therapy Processing Systems Market: Share of Cryopreservation Systems, Till 2035 (USD Million)
Table 14.41. Automated and Closed Cell Therapy Processing Systems Market: Share of Thawing Systems, Till 2035 (USD Million)
Table 14.42. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Scale of Operation (USD Million)
Table 14.43. Automated and Closed Cell Therapy Processing Systems Market: Share of Preclinical / Clinical Scale Operations, Till 2035 (USD Million)
Table 14.44. Automated and Closed Cell Therapy Processing Systems Market: Share of Commercial Operations, Till 2035 (USD Million)
Table 14.45. Automated and Closed Cell Therapy Processing Systems Market: Distribution by End User (USD Million)
Table 14.46. Automated and Closed Cell Therapy Processing Systems Market: Share of Hospitals / Medical Centers / Clinics / Research Institutes / Academic Institutes, Till 2035 (USD Million)
Table 14.47. Automated and Closed Cell Therapy Processing Systems Market: Share of Commercial Organizations, Till 2035 (USD Million)
Table 14.48. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Key Geographical Regions (USD Million)
Table 14.49. Automated and Closed Cell Therapy Processing Systems Market: Share of North America, Till 2035 (USD Million)
Table 14.50. Automated and Closed Cell Therapy Processing Systems Market: Share of Europe, Till 2035 (USD Million)
Table 14.51. Automated and Closed Cell Therapy Processing Systems Market: Share of Asia-Pacific, Till 2035 (USD Million)
Table 14.52. Automated and Closed Cell Therapy Processing Systems Market: Share of LATAM, Till 2035 (USD Million)
Table 14.53. Automated and Closed Cell Therapy Processing Systems Market: Share of MENA, Till 2035 (USD Million)

List of Figures

Figure 3.1. Key Steps Involved in Manufacturing of Cell Therapies
Figure 3.2. Key Considerations while Automating Cell Therapy Manufacturing Process
Figure 3.3. Role of Automated and Closed Systems across Each Cell Therapy Processing Step
Figure 3.4. Advantages offered by Automated and Closed Cell Processing Systems
Figure 3.5. Challenges Associated with Automated and Closed Cell Processing Systems
Figure 3.6. Growth Drivers and Roadblocks in the Automated and Closed Systems Market
Figure 4.1. Automated and Closed Cell Therapy Processing Systems: Distribution by Cell Processing Step
Figure 4.2. Automated and Closed Cell Therapy Processing Systems: Distribution by Types of Cells
Figure 4.3. Automated and Closed Cell Therapy Processing Systems: Distribution by Type of Culture
Figure 4.4. Automated and Closed Cell Therapy Processing Systems: Distribution by Scale of Operation
Figure 4.5. Automated and Closed Cell Therapy Processing Systems: Distribution by Key Features
Figure 4.6. Automated and Closed Cell Therapy Processing Systems: Distribution by Application Area
Figure 4.7. Automated and Closed Cell Therapy Processing Systems: Distribution by Regulatory Certifications / Accreditations
Figure 4.8. Automated and Closed Cell Therapy Processing Systems: Distribution by End Users
Figure 4.9. Automated and Closed Cell Therapy Processing System Providers: Distribution by Year of Establishment
Figure 4.10. Automated and Closed Cell Therapy Processing System Providers: Distribution by Company Size
Figure 4.11. Automated and Closed Cell Therapy Processing System Providers: Distribution by Type of Support Services Offered
Figure 4.12. Automated and Closed Cell Therapy Processing System Providers: Distribution by Geographical Location
Figure 4.13. Automated and Closed Cell Therapy Processing System Providers: Distribution by Geographical Location (Country-Wise)
Figure 4.14. Leading Developers: Distribution by Number of Automated and Closed Cell Therapy Processing Systems
Figure 5.1. Product Competitiveness Analysis: Automated and Closed Systems for Cell Apheresis
Figure 5.2. Product Competitiveness Analysis: Automated and Closed Systems for Cell Separation
Figure 5.3. Product Competitiveness Analysis: Automated and Closed Systems for Cell Expansion
Figure 5.4. Product Competitiveness Analysis: Automated and Closed Systems for Cell Harvesting
Figure 5.5. Product Competitiveness Analysis: Automated and Closed Systems for Fill Finish
Figure 5.6. Product Competitiveness Analysis: Automated and Closed Systems for Cryopreservation
Figure 5.7. Product Competitiveness Analysis: Automated and Closed Systems for Thawing
Figure 6.1. Terumo BCT: Annual Revenues, Since FY 2016
Figure 6.2. ThermoGenesis: Annual Revenues, Since FY 2016
Figure 7.1. Recent Partnerships: Cumulative Distribution by Year of Partnership
Figure 7.2. Recent Partnerships: Distribution by Type of Partnership Model Adopted
Figure 7.3. Recent Partnerships: Year-wise Trend by Type of Partnership Model Adopted
Figure 7.4. Recent Partnerships: Distribution by Type of Therapy
Figure 7.5. Recent Partnerships: Distribution by Type of Therapy and Type of Partnership Model Adopted
Figure 7.6. Recent Partnerships: Distribution by Cell Processing Step
Figure 7.7. Recent Partnerships: Distribution by Automated and Closed Cell Processing System
Figure 7.8. Recent Partnerships: Distribution by Type of Partner
Figure 7.9. Recent Partnerships: Distribution by Type of Cell Processing Step and Developer
Figure 7.10. Recent Partnerships: Most Active Players
Figure 7.11. Recent Partnerships: Country-Wise Distribution
Figure 7.12. Recent Partnerships: Intercontinental and Intracontinental Distribution
Figure 8.1. Big Pharma Initiatives Summary
Figure 10.1. Cost Saving Analysis: Comparative Analysis of Manual, Partially Automated and Fully Automated Processing Systems, Till 2035
Figure 10.2. Cost Saving Potential of Fully Automated Processing Systems Based on Number of Patients
Figure 10.3. Cost Saving Potential of Fully Automated Processing Systems Across Different Regions
Figure 11.1. Overall Automated and Closed Cell Therapy Processing Systems Market, Till 2035 (USD Million)
Figure 11.2. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Cell Therapy Processing Step (USD Million)
Figure 11.3. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Apheresis Systems, Till 2035 (USD Million)
Figure 11.4. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Separation Systems, Till 2035 (USD Million)
Figure 11.5. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Expansion Systems, Till 2035 (USD Million)
Figure 11.6. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Harvesting Systems, Till 2035 (USD Million)
Figure 11.7. Automated and Closed Cell Therapy Processing Systems Market: Share of Fill Finish Systems, Till 2035 (USD Million)
Figure 11.8. Automated and Closed Cell Therapy Processing Systems Market: Share of Cryopreservation Systems, Till 2035 (USD Million)
Figure 11.9. Automated and Closed Cell Therapy Processing Systems Market: Share of Thawing Systems, Till 2035 (USD Million)
Figure 11.10. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Scale of Operation (USD Million)
Figure 11.11. Automated and Closed Cell Therapy Processing Systems Market: Share of Preclinical / Clinical Scale Operations, Till 2035 (USD Million)
Figure 11.12. Automated and Closed Cell Therapy Processing Systems Market: Share of Commercial Operations, Till 2035 (USD Million)
Figure 11.13. Automated and Closed Cell Therapy Processing Systems Market: Distribution by End User (USD Million)
Figure 11.14. Automated and Closed Cell Therapy Processing Systems Market: Share of Hospitals / Medical Centers / Clinics / Research Institutes / Academic Institutes, Till 2035 (USD Million)
Figure 11.16. Automated and Closed Cell Therapy Processing Systems Market: Share of Commercial Organizations, Till 2035 (USD Million)
Figure 11.17. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Key Geographical Regions (USD Million)
Figure 11.18. Automated and Closed Cell Therapy Processing Systems Market: Share of North America, Till 2035 (USD Million)
Figure 11.19. Automated and Closed Cell Therapy Processing Systems Market: Share of Europe, Till 2035 (USD Million)
Figure 11.20. Automated and Closed Cell Therapy Processing Systems Market: Share of Asia-Pacific, Till 2035 (USD Million)
Figure 11.21. Automated and Closed Cell Therapy Processing Systems Market: Share of LATAM, Till 2035 (USD Million)
Figure 11.22. Automated and Closed Cell Therapy Processing Systems Market: Share of MENA, Till 2035 (USD Million)

Product Code: RA100227

AUTOMATED CELL PROCESSING SYSTEM MARKET: OVERVIEW

As per Roots Analysis, the global automated cell processing system market valued at USD 220 million in the current year is projected to grow at a CAGR of 16% during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Cell Therapy Processing Step

Apheresis
Separation
Expansion
Harvest
Fill / Finish
Cryopreservation
Thawing

Scale of Operation

Pre-clinical / Clinical Operations
Commercial Organizations

End User

Hospitals / Medical Centers / Clinics / Research Institutes / Academic Institutes
Cell Therapy Manufacturers / Developers

Key Geographical Regions

North America
Europe
Asia-Pacific
Latin America
Middle East and North Africa

AUTOMATED CELL PROCESSING SYSTEM MARKET: GROWTH AND TRENDS

Recently there has been a rise in the number of cell therapies candidates, driven by numerous developmental breakthroughs in the biotechnology industry. In fact, more than 2,000 cell and gene therapy candidates are currently being investigated for the treatment of a myriad of disease indications. Further, the results of FDA approved therapies demonstrated the vast potential of cellular therapies in the treatment of oncological disorders, rare diseases, and chronic diseases. Thus, this therapeutic modality has garnered considerable attention from players engaged in the healthcare industry in the past few years. However, the conventional cell therapy manufacturing process is labor-intensive and time-consuming which results in high cost of production. Moreover, this manual process of cell therapy manufacturing leads to batch-to-batch variation. Consequently, there is an emerging and pressing need for more sophisticated and time efficient solutions for production.

Over the years, several advanced and innovative automation tools and technologies have been developed. These automated and closed cell processing systems have been demonstrated to hold the potential for significant reduction in the cost associated with the manufacturing of advanced cell therapies. One such automated system, namely GMP-In-A Box, offers several advantages, including increased throughput, decreased idle time between batch runs and reduced manual labor. Owing to such benefits of automation, the cell processing systems market is poised to witness lucrative growth in the coming future.

AUTOMATED CELL PROCESSING SYSTEM MARKET: KEY INSIGHTS

The report delves into the current state of the automated cell processing system market and identifies potential growth opportunities within industry. Some key findings from the report include:

Presently, over 60 innovative, automated and closed systems have been developed by different companies in order to automate various stages of cell therapy development, production, and cryopreservation.
The market landscape is fragmented, featuring both established players and new entrants, engaged in developing novel technologies with distinct features, for processing cells across different scales of operation.
Since 2010, many startups, focused on developing automated and closed cell processing systems, have been established; this upcoming domain has captured the interest of both big and small players.
Majority of the available systems are compliant with the current regulatory requirements; examples include BATON, NANT 001, robotic cell culture systems and the volta loop.
The increasing interest of stakeholders in this field is also reflected in the recent partnership activity; most recent deals are focused on novel technologies and involve the active participation of both international and indigenous players.

The number of partnerships in this domain have increased at a CAGR of 24%; more than 70% of these partnerships have been signed since 2018.
Several deals focused on utilization or integration of SA25 aseptic filling work cell (vanrx pharma systems) were signed for fill / finish of cell therapy products.
In pursuit of a competitive advantage, equipment developers are presently focusing on the integration of advanced features into their respective products and affiliated offerings.
An evaluation of more than 300+ stakeholders engaged in the development of cell therapies, including big pharma players, reveals several likely strategic partnership opportunities for equipment providers in this field.
Given their cost saving potential across different processing steps, we expect the automated and closed cell therapy systems market to grow at an annualized rate of 16% over the next decade.

Example Players in the Automated Cell Processing System Market

AstraZeneca
Baxter
Bayer
Cytiva (Acquired by Danaher Corporation)
Cellular Therapeutics
Lonza
Merck
Pall (Acquired by Danaher Corporation)
Terumo BCT
ThermoGenesis

AUTOMATED CELL PROCESSING SYSTEM MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global automated cell processing system market, focusing on key market segments, including [A] cell therapy processing step, [B] scale of operation, [C] end user and [D] key geographical regions.
Market Landscape: A comprehensive evaluation of the automated and closed systems, based on several relevant parameters, such as [A] cell therapy processing step, [B] their key features, [C] product specifications, [D] type of cells supported, [E] type of cell culture, [F] scale of operation, [G] application, [H] end users, [I] key support services offered and [J] regulatory certification / accreditations obtained.
Product Competitiveness Analysis: A comprehensive competitive analysis of automated and closed systems, examining factors, such as [A] supplier power and [B] portfolio-related parameters.
Company Profiles: In-depth profiles of key players that are engaged in offering automated and closed cell therapy processing systems, focusing on [A] overview of the company, [B] financial information (if available), [C] detailed description of the system(s) they offer and [D] recent developments and an informed future outlook.
Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in the automated cell processing system market, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] type of therapy, [D] type of cell processing step, [E] key automated and closed cell processing systems, [F] partner's focus area, [G] most active players (in terms of number of partnerships signed), and [H] geographical location of collaborators.
Big Pharma Initiatives: A comprehensive evaluation of recent initiatives undertaken by big pharma players engaged in the automated cell processing system market.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
- 1.2.1. Research Assumptions
- 1.2.2. Project Methodology
- 1.2.3. Forecast Methodology
- 1.2.4. Robust Quality Control
- 1.2.5. Key Considerations
  - 1.2.5.1. Demographics
  - 1.2.5.2. Economic Factors
  - 1.2.5.3. Government Regulations
  - 1.2.5.4. Supply Chain
  - 1.2.5.6. COVID Impact / Related Factors
  - 1.2.5.7. Market Access
  - 1.2.5.8. Healthcare Policies
  - 1.2.5.9. Industry Consolidation
1.3 Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Context and Background
3.2. Cell Therapies
3.3. Cell Therapy Manufacturing
3.4. Key Challenges Associated with Manufacturing Cell Therapies
3.5. Overview of Automated and Closed Cell Processing Systems
- 3.5.1. Need for Automated and Closed Cell Processing in Cell Therapy Manufacturing
- 3.5.2. Advantages and Affiliated Challenges
3.6. Key Growth Drivers and Roadblocks
3.7. Recent Developments and Upcoming Trends

4. COMPETITIVE LANDSCAPE

4.1. Chapter Overview
4.2. Automated and Closed Cell Therapy Processing Systems: Overall Market Landscape
- 4.2.1. Analysis by Cell Processing Step
- 4.2.2. Analysis by Types of Cells
- 4.2.3. Analysis by Type of Culture
- 4.2.4. Analysis by Scale of Operation
- 4.2.5. Analysis by Key Features
- 4.2.6. Analysis by Application Area
- 4.2.7. Analysis by Regulatory Certifications / Accreditations
- 4.2.8. Analysis by End User
4.3. Automated and Closed Cell Therapy Processing Systems: Developer Landscape
- 4.3.1. Analysis by Year of Establishment
- 4.3.2. Analysis by Company Size
- 4.3.3. Analysis by Type of Support Service(s) Offered
- 4.3.4. Analysis by Location of Headquarters

5. PRODUCT COMPETITIVENESS ANALYSIS

5.1. Chapter Overview
5.2. Assumptions / Key Parameters
5.3. Methodology
5.4. Product Competitiveness Analysis
- 5.4.1. Automated and Closed Cell Processing Systems for Apheresis
- 5.4.2. Automated and Closed Cell Processing Systems for Separation
- 5.4.3. Automated and Closed Cell Processing Systems for Expansion
- 5.4.4. Automated and Closed Cell Processing Systems for Harvest
- 5.4.5. Automated and Closed Cell Processing Systems for Fill Finish
- 5.4.6. Automated and Closed Cell Processing Systems for Cryopreservation
- 5.4.7. Automated and Closed Cell Processing Systems for Thawing

6. COMPANY PROFILES

6.1. Chapter Overview
6.2. Cytiva
- 6.2.1. Company Overview
- 6.2.2. Product Portfolio
- 6.2.3. Recent Developments and Future Outlook
6.3. Pall
- 6.3.1. Company Overview
- 6.3.2. Product Portfolio
- 6.3.3. Recent Developments and Future Outlook
6.4. Terumo BCT
- 6.4.1. Company Overview
- 6.4.2. Product Portfolio
- 6.4.3. Financial Information
- 6.4.4. Recent Developments and Future Outlook
6.5 ThermoGenesis
- 6.5.1. Company Overview
- 6.5.2. Product Portfolio
- 6.5.3. Financial Information
- 6.5.4. Recent Developments and Future Outlook

7. PARTNERSHIPS

7.1. Chapter Overview
7.2. Partnership Models
7.3. Automated and Closed Cell Therapy Processing Systems: Recent Partnerships
- 7.3.1. Analysis by Year of Partnership
- 7.3.2. Analysis by Type of Partnership
- 7.3.3. Analysis by Type of Therapy
- 7.3.4. Analysis by Cell Processing Step
- 7.3.5. Analysis by Type of Automated and Closed Cell Processing Systems
- 7.3.6. Analysis by Partner's Focus Area
- 7.3.7. Most Active Players: Analysis by Number of Partnerships
- 7.3.8. Geographical Analysis
  - 7.3.8.1. Country-Wise Distribution
  - 7.3.8.2. Intercontinental and Intracontinental Agreements

8. BIG PHARMA INITIATIVES IN AUTOMATED AND CLOSED CELL THERAPY PROCESSING SYSTEMS DOMAIN

8.1. Chapter Overview
8.2. Initiatives Undertaken by Big Pharma Players
- 8.2.1. Initiatives Undertaken by AbbVie
- 8.2.2. Initiatives Undertaken by Bristol Myers Squibb
- 8.2.3. Initiatives Undertaken by Gilead Sciences
- 8.2.4. Initiatives Undertaken by GlaxoSmithKline
- 8.2.5. Initiatives Undertaken by Johnson & Johnson
- 8.2.6. Initiatives Undertaken by Novartis
- 8.2.7. Initiatives Undertaken by Roche
- 8.2.8. Initiatives Undertaken by Sanofi
- 8.2.9. Initiatives Undertaken by Takeda Pharmaceutical
- 8.2.10. Summary of Big Pharma Initiatives

9. LIKELY PARTNER

9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Automated and Closed Cell Therapy Processing Systems: Potential Strategic Partners for Cell Therapy Development
- 9.3.1. Dendritic Cell Therapy
- 9.3.2. Stem Cell Therapy
- 9.3.3. T-cell Therapy
- 9.3.4. Natural Killer Cell Therapy
9.4. Automated and Closed Cell Therapy Processing Systems: Potential Strategic Partners for Cell Therapy Manufacturing
- 9.4.1. Dendritic Cell Therapy
- 9.4.2. Stem Cell Therapy,
- 9.4.3. T-cell Therapy
- 9.4.4. Natural Killer Cell Therapy

10. CASE STUDY: COST BENEFIT ANALYSIS USING PARTIALLY AUTOMATED AND FULLY AUTOMATED SYSTEMS

10.1. Chapter Overview
10.2. Comparative Analysis of Manual, Partially Automated and Fully Automated Cell Processing Systems
10.3. Likely Cost Saving Potential for Kymriah(R)
10.4. Likely Cost Saving Potential for Yescarata(R)
10.5. Cost Saving Potential of Fully Automated Processing Systems: Regional Trends
10.6. Concluding Remarks

11. MARKET SIZING AND OPPORTUNITY ANALYSIS

11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Overall Automated and Closed Cell Therapy Processing Systems Market, Till 2035
- 11.3.1. Overall Automated and Closed Cell Therapy Processing Systems Market: Distribution by Cell Therapy Processing Step
  - 11.3.1.1. Automated and Closed Cell Therapy Processing Systems Market for Apheresis, Till 2035
  - 11.3.1.2. Automated and Closed Cell Therapy Processing Systems Market for Separation, Till 2035
  - 11.3.1.3. Automated and Closed Cell Therapy Processing Systems Market for Expansion, Till 2035
  - 11.3.1.4. Automated and Closed Cell Therapy Processing Systems Market for Harvest, Till 2035
  - 11.3.1.5. Automated and Closed Cell Therapy Processing Systems Market for Fill / Finish, Till 2035
  - 11.3.1.6. Automated and Closed Cell Therapy Processing Systems Market for Cryopreservation, Till 2035
  - 11.3.1.7. Automated and Closed Cell Therapy Processing Systems Market for Thawing, Till 2035
- 11.3.2. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Scale of Operation
  - 11.3.2.1. Automated and Closed Cell Therapy Processing Systems Market for Pre-clinical / Clinical Operations, Till 2035
  - 11.3.2.2. Automated and Closed Cell Therapy Processing Systems Market for Commercial Operations, Till 2035
- 11.3.3. Automated and Closed Cell Therapy Processing Systems Market: Distribution by End User
  - 11.3.3.1. Automated and Closed Cell Therapy Processing Systems Market for Hospitals / Medical Centers / Clinics / Research Institutes / Academic Institutes, Till 2035
  - 11.3.3.2. Automated and Closed Cell Therapy Processing Systems Market for Cell Therapy Manufacturers / Developers, Till 2035
- 11.3.4. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Key Geographic Regions
  - 11.3.4.1. Automated and Closed Cell Therapy Processing Systems Market in North America, Till 2035
  - 11.3.4.2. Automated and Closed Cell Therapy Processing Systems Market in Europe, Till 2035
  - 11.3.4.3. Automated and Closed Cell Therapy Processing Systems Market in Asia-Pacific, Till 2035
  - 11.3.4.4. Automated and Closed Cell Therapy Processing Systems Market in Latin America (LATAM), Till 2035
  - 11.3.4.5. Automated and Closed Cell Therapy Processing Systems Market in Middle East North America (MENA), Till 2035

自動細胞処理システム市場業界動向と世界の予測 - 細胞治療処理ステップ別、事業規模別、エンドユーザー別、主要地域別

Automated Cell Processing System Market: Industry Trends and Global Forecasts - Distribution by Cell Therapy Processing Step, Scale of Operation, End User and Key Geographical Regions

自動細胞処理システム市場：概要

自動細胞処理システム市場：成長と動向

自動細胞処理システム市場：主要インサイト

自動細胞処理システム市場の参入企業例

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 競合情勢

第5章 製品競争力分析

第6章 企業プロファイル

第7章 パートナーシップ

第8章 自動化および閉鎖型細胞治療処理システム分野における大手製薬会社の取り組み

第9章 パートナー候補

第10章 ケーススタディ：部分自動化システムと完全自動化システムを使用した費用便益分析

第11章 市場規模の評価と機会分析

第12章 結論

第13章 インタビュー/アンケート記録

第14章 付録1：表形式データ

第15章 付録2：企業・団体一覧

List of Tables

List of Figures

AUTOMATED CELL PROCESSING SYSTEM MARKET: OVERVIEW

AUTOMATED CELL PROCESSING SYSTEM MARKET: GROWTH AND TRENDS

AUTOMATED CELL PROCESSING SYSTEM MARKET: KEY INSIGHTS

Example Players in the Automated Cell Processing System Market

AUTOMATED CELL PROCESSING SYSTEM MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

TABLE OF CONTENTS

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. COMPETITIVE LANDSCAPE

5. PRODUCT COMPETITIVENESS ANALYSIS

6. COMPANY PROFILES

7. PARTNERSHIPS

8. BIG PHARMA INITIATIVES IN AUTOMATED AND CLOSED CELL THERAPY PROCESSING SYSTEMS DOMAIN

9. LIKELY PARTNER

10. CASE STUDY: COST BENEFIT ANALYSIS USING PARTIALLY AUTOMATED AND FULLY AUTOMATED SYSTEMS

11. MARKET SIZING AND OPPORTUNITY ANALYSIS

12. CONCLUSION

13. INTERVIEW / SURVEY TRANSCRIPT(S)

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

第1章序文

第2章エグゼクティブサマリー

第3章イントロダクション

第4章競合情勢

第5章製品競争力分析

第6章企業プロファイル

第7章パートナーシップ

第8章自動化および閉鎖型細胞治療処理システム分野における大手製薬会社の取り組み